NCT04124484 - DBPR108 Tablets in Type 2 Diabetes Mellitus Patients | Biotech Hunter

Enrollment

276

Participants

Timeline

Start Date

October 17, 2017

Primary Completion Date

February 27, 2019

Study Completion Date

June 28, 2019

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)

One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks

DRUG

DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)

One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks

DRUG

DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)

Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks

DRUG

Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)

Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks

Trial Locations (1)

Unknown

First Hospital of Peking Unversity, Beijing

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY